APIM Therapeutics's abstract summarizing results from our first-in-human clinical study with ATX-101 in advanced cancer patients has now been posted on the website of the American Society of Clinical Oncology (ASCO) Annual Meeting (please follow this link). The corresponding poster will be presented at the Developmental Therapeutics-Molecular Targeted Agents and Tumor Biology Session on June 4, starting at 3:00 pm.
